JP2025511190A5 - - Google Patents

Info

Publication number
JP2025511190A5
JP2025511190A5 JP2024558027A JP2024558027A JP2025511190A5 JP 2025511190 A5 JP2025511190 A5 JP 2025511190A5 JP 2024558027 A JP2024558027 A JP 2024558027A JP 2024558027 A JP2024558027 A JP 2024558027A JP 2025511190 A5 JP2025511190 A5 JP 2025511190A5
Authority
JP
Japan
Prior art keywords
terminus
domain
directly
target
indirectly coupled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065191 external-priority patent/WO2023192973A1/en
Publication of JP2025511190A publication Critical patent/JP2025511190A/ja
Priority to JP2026057639A priority Critical patent/JP2026099822A/ja
Publication of JP2025511190A5 publication Critical patent/JP2025511190A5/ja
Pending legal-status Critical Current

Links

JP2024558027A 2022-04-01 2023-03-31 活性化可能な多重特異性分子及びその使用方法 Pending JP2025511190A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026057639A JP2026099822A (ja) 2022-04-01 2026-03-31 活性化可能な多重特異性分子及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326692P 2022-04-01 2022-04-01
US63/326,692 2022-04-01
PCT/US2023/065191 WO2023192973A1 (en) 2022-04-01 2023-03-31 Activatable multispecific molecules and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026057639A Division JP2026099822A (ja) 2022-04-01 2026-03-31 活性化可能な多重特異性分子及びその使用方法

Publications (2)

Publication Number Publication Date
JP2025511190A JP2025511190A (ja) 2025-04-15
JP2025511190A5 true JP2025511190A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=86272372

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024558027A Pending JP2025511190A (ja) 2022-04-01 2023-03-31 活性化可能な多重特異性分子及びその使用方法
JP2026057639A Pending JP2026099822A (ja) 2022-04-01 2026-03-31 活性化可能な多重特異性分子及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026057639A Pending JP2026099822A (ja) 2022-04-01 2026-03-31 活性化可能な多重特異性分子及びその使用方法

Country Status (5)

Country Link
US (1) US20250215110A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504257A1 (cg-RX-API-DMAC7.html)
JP (2) JP2025511190A (cg-RX-API-DMAC7.html)
CN (1) CN119300859A (cg-RX-API-DMAC7.html)
WO (1) WO2023192973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026024841A1 (en) * 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
US20190031785A1 (en) * 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CN110072890B (zh) 2016-11-03 2022-11-29 百时美施贵宝公司 可活化的抗ctla-4抗体及其用途
JP2020511130A (ja) 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
JP2020530554A (ja) 2017-07-20 2020-10-22 シートムエックス セラピューティクス,インコーポレイテッド 活性化抗体の特性を定性的および/または定量的に分析する方法およびその使用
CN111212853A (zh) 2017-08-30 2020-05-29 西托姆克斯治疗公司 可活化的抗cd166抗体及其使用方法
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20200405890A1 (en) 2018-02-21 2020-12-31 Cytomx Therapeutics, Inc. Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
CN112005304A (zh) 2018-03-20 2020-11-27 西托姆克斯治疗公司 用于哺乳动物受试者中的可活化抗体种类的定量药理学建模的系统和方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
BR112021008526A2 (pt) 2018-11-02 2021-08-10 Cytomx Therapeutics, Inc. anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
WO2020236679A1 (en) 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
WO2020252358A1 (en) 2019-06-13 2020-12-17 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer
US20220306745A1 (en) 2019-06-13 2022-09-29 Cytomx Therapeutics, Inc. Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
EP4034171A1 (en) 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
AU2021206218A1 (en) 2020-01-06 2022-07-07 Cytomx Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021087429A5 (cg-RX-API-DMAC7.html)
JP2019513014A5 (cg-RX-API-DMAC7.html)
JP2023526428A5 (cg-RX-API-DMAC7.html)
US20250163153A1 (en) Release segments and binding compositions comprising same
US12215156B2 (en) HER-2 targeted bispecific compositions and methods for making and using the same
IL307276B2 (en) Chimeric polypeptide assembly and methods of making and using the same
JP2023511074A (ja) 切断可能リンカーを含むサイトカインプロドラッグ
JP7855148B2 (ja) 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
JP2025511187A5 (cg-RX-API-DMAC7.html)
US12590159B2 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
JP2025511713A5 (cg-RX-API-DMAC7.html)
JP2023532021A (ja) プロテアーゼ感受性が低減された組換えシアリダーゼ、シアリダーゼ融合タンパク質、及びその使用方法
JP2024531338A5 (cg-RX-API-DMAC7.html)
RU2020123264A (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
WO2023183888A1 (en) Activatable antigen-binding protein constructs and uses of the same
CN119300859A (zh) 可激活多特异性分子和其使用方法
WO2026024863A2 (en) Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
NZ738945B2 (en) Chimeric polypeptide assembly and methods of making and using the same
NZ779352B2 (en) Chimeric polypeptide assembly and methods of making and using the same